Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation

被引：5

作者：

Wolf, J. ^{[1
]}

Heist, R. ^{[2
]}

Kim, T. M. ^{[3
]}

Nishio, M. ^{[4
]}

Dooms, C. ^{[5
]}

Kanthala, R. R. ^{[6
]}

Leo, E. ^{[7
]}

Giorgetti, E. ^{[7
]}

Wang, Y. ^{[8
]}

Mardjuadi, F. I. ^{[8
]}

Cortot, A. ^{[9
]}

机构：

[1] Univ Klinikum Koln AoR, Dept Internal Med 1, Ctr Integrated Oncol, Cologne, Germany

[2] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA

[3] Seoul Natl Univ, Coll Med, Dept Internal Med, Yeongeon Med Campus, Seoul, South Korea

[4] JFCR, Canc Inst Hosp, Dept Thorac Med Oncol, Koto Ku, Tokyo, Japan

[5] Univ Hosp Leuven, UZ Leuven, Dept Resp Dis, Campus Gasthuisberg, Leuven, Belgium

[6] Novartis Healthcare Pvt Ltd, GDO DO Stat Programming, Hyderabad, Telangana, India

[7] Novartis Pharma AG, Oncol, Basel, Switzerland

[8] Novartis Inst BioMed Res Co Ltd, Oncol, Shanghai, Peoples R China

[9] Univ Lille, CHU Lille, Thorac Oncol Dept,Inst Pasteur Lille, CNRS,Inserm,UMR9020,UMR S 1277 Canther, Lille, France

来源：

关键词：

D O I：

10.1016/j.annonc.2022.07.1120

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

994P

引用

页码：S1007 / S1008

页数：2